SCHEDULE 13G/A: Redmile Group Maintains Significant Stake in Neurogene Inc., Holding 9.9% of Common Stock
Beneficial Ownership Report
Redmile Group, LLC and its affiliates, including Jeremy C. Green and Redmile Biopharma Investments I, L.P., have filed an amended Schedule 13G, confirming their beneficial ownership of 9.9% of Neurogene Inc.'s common stock as of December 31, 2024.
Summary
- Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments I, L.P. collectively reported beneficial ownership of 1,479,766 shares of Neurogene Inc. common stock.
- This aggregate ownership represents 9.9% of Neurogene Inc.'s outstanding common stock.
- The ownership is comprised of 1,319,763 shares of common stock and 160,003 shares issuable upon exercise of warrants.
- Redmile Biopharma Investments I, L.P. directly holds 812,033 shares, representing 5.4% of the class, including 652,030 common shares and 160,003 warrant shares.
- The percentage ownership is calculated based on 14,854,725 shares of common stock outstanding as of December 1, 2024, plus the 160,003 shares issuable from warrants.
- The filing is an Amendment No. 5 to a Schedule 13G, indicating an update to a previously reported passive investment stake.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive as it indicates continued institutional confidence in Neurogene Inc. through a significant, albeit passive, ownership stake. It's a routine disclosure, but the presence of a dedicated biopharma investor is generally viewed favorably.
Positives
- Continued significant institutional investment by Redmile Group, a specialized healthcare investor, may signal confidence in Neurogene Inc.'s long-term prospects.
- The passive nature of the investment, as indicated by the 13G filing, suggests no immediate intent to influence or change control of the issuer.
Risks
- Concentration of ownership, while passive, means a significant portion of the company's stock is held by a single investment group, which could impact liquidity or trading dynamics if the group were to significantly alter its position.
Future Outlook
NA
Industry Context
The filing reflects ongoing investment activity by specialized healthcare funds in biotechnology companies like Neurogene Inc. Such investments are common in the biopharma sector, where long-term capital is often required for drug development and clinical trials. Redmile Group's continued stake suggests a sustained interest in the sector and potentially in Neurogene's specific therapeutic areas.
Stakeholder Impact
- Shareholders: The continued significant stake by Redmile Group may provide a level of stability and confidence, as it represents a substantial long-term investment by a specialized fund.
- Management: Awareness of a large, passive institutional investor may influence strategic decisions, though the 13G nature implies no direct control intent.
Key Dates
| Date | Description |
|---|---|
| 2024-12-01 | Date as of which 14,854,725 shares of Common Stock were reported outstanding by Neurogene Inc. in its Prospectus Supplement. |
| 2024-12-18 | Date of filing of Neurogene Inc.'s Prospectus Supplement with the SEC. |
| 2024-12-31 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-02-14 | Date of signing and filing of this Schedule 13G Amendment No. 5. |
Keywords
Neurogene Inc., Redmile Group, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investment, Biopharma, Healthcare Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.